BioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC, Université de Strasbourg , 25 rue Becquerel, 67087 Strasbourg, France.
Anal Chem. 2014 Nov 4;86(21):10674-83. doi: 10.1021/ac502593n. Epub 2014 Oct 21.
Antibody drug conjugates (ADCs) are macromolecules composed of cytotoxic drugs covalently attached via a conditionally stable linker to monoclonal antibodies (mAbs). ADCs are among the most promising next generation of empowered mAbs foreseen to treat cancers. Compared to naked mAbs, ADCs have an increased level of complexity as the heterogeneity of conjugation cumulates with the inherent microvariability of the biomolecule. An increasing need underlying ADC's development and optimization is to improve its analytical and bioanalytical characterization by assessing three main ADC quality attributes: drug distribution, amount of naked antibody, and average drug to antibody ratio (DAR). Here, the analytical potential of native mass spectrometry (MS) and native ion mobility MS (IM-MS) is compared to hydrophobic interaction chromatography (HIC), the reference method for quality control of interchain cysteinyl-linked ADCs. Brentuximab vedotin, first in class and gold standard, was chosen for a proof of principle. High resolution native MS provided accurate mass measurement (<30 ppm) of intact ADCs together with average DAR and drug distribution, confirming the unique ability of native MS for simultaneous detection of mixtures of covalent and noncovalent products. Native IM-MS was next used for the first time to characterize an ADC. IM-MS evidenced ADC multiple drug loading, collisional cross sections measurement of each payload species attesting slight conformational changes. A semiquantitative interpretation of IM-MS data was developed to directly extrapolate average DAR and DAR distribution. Additionally, HIC fractions were collected and analyzed by native MS and IM-MS, assessing the interpretation of each HIC peak. Altogether, our results illustrate how native MS and IM-MS can rapidly assess ADC structural heterogeneity and how easily these methods can be implemented into MS workflows for in-depth ADC analytical characterization.
抗体药物偶联物 (ADC) 是由通过条件稳定的连接子共价连接的细胞毒性药物和单克隆抗体 (mAb) 组成的大分子。与裸单抗相比,ADC 具有更高的复杂性,因为连接的不均一性与生物分子固有的微变异性累积。ADC 开发和优化的一个日益增长的需求是通过评估三个主要 ADC 质量属性来提高其分析和生物分析特性:药物分布、裸抗体的量和平均药物与抗体比 (DAR)。在这里,将比较天然质谱 (MS) 和天然离子淌度 MS (IM-MS) 的分析潜力与疏水性相互作用色谱 (HIC),后者是链间半胱氨酸连接的 ADC 质量控制的参考方法。选择首类和金标准药物 Brentuximab vedotin 进行原理验证。高分辨率天然 MS 提供了完整 ADC 的精确质量测量 (<30 ppm) 以及平均 DAR 和药物分布,证实了天然 MS 同时检测共价和非共价产物混合物的独特能力。接下来,首次将天然 IM-MS 用于 ADC 的表征。IM-MS 证明了 ADC 的多药物加载,每个有效载荷物种的碰撞截面测量证明了轻微的构象变化。开发了一种半定量解释 IM-MS 数据的方法,可直接推断平均 DAR 和 DAR 分布。此外,还通过天然 MS 和 IM-MS 收集和分析 HIC 馏分,评估每个 HIC 峰的解释。总之,我们的结果说明了天然 MS 和 IM-MS 如何快速评估 ADC 的结构异质性,以及这些方法如何轻松地被纳入 MS 工作流程,以进行深入的 ADC 分析表征。